Moxifloxacin
Moxifloxacin hydrochloride
Brand names:Avelox, Vigamox
A fourth-generation fluoroquinolone antibiotic historically used in TCCC for combat wound prophylaxis. Moxifloxacin offers broad spectrum coverage with once-daily dosing. Its role in TCCC has diminished in recent guideline updates in favor of cefadroxil for routine oral wound prophylaxis, but moxifloxacin remains relevant for prolonged field care and as an alternative in penicillin/cephalosporin allergy.
Pharmacology and Actions
Moxifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, blocking DNA replication and transcription. The result is bactericidal activity against a broad range of gram-positive, gram-negative, and atypical pathogens. Moxifloxacin has enhanced gram-positive activity compared to earlier fluoroquinolones (ciprofloxacin), particularly against Streptococcus pneumoniae, making it well-suited for community-acquired respiratory infections.
Indications
- Combat wound infection prophylaxis (historical TCCC indication; superseded by cefadroxil)
- Community-acquired pneumonia in tactical or austere environments
- Complicated skin and soft tissue infections
- Intra-abdominal infections (often combined with metronidazole)
- Alternative oral antibiotic in penicillin and cephalosporin allergy
- Anthrax post-exposure prophylaxis (deployment medicine)
Absolute Contraindications
- Known fluoroquinolone allergy
- Prolonged QT interval or concurrent QT-prolonging medications
- History of fluoroquinolone-associated tendon rupture or tendinopathy
- Pediatric patients under 18 years (relative; reserved for serious indications)
- Pregnancy and breastfeeding
Precautions and Side Effects
Black box warnings include tendinopathy and tendon rupture (especially Achilles), peripheral neuropathy, CNS effects (seizures, confusion, hallucinations), and exacerbation of myasthenia gravis. QT interval prolongation can occur. Photosensitivity and rash are common. The FDA has restricted fluoroquinolone use for uncomplicated infections because of these adverse effects. Hypoglycemia and hyperglycemia have been reported. Avoid in patients at high risk of seizure or with significant QT-prolonging medication burden.
Adult Dosing
Pediatric Dosing
Moxifloxacin is generally avoided in pediatric patients under 18 due to fluoroquinolone class effects on developing cartilage. Pediatric use is restricted to serious infections without safer alternatives, under specialist guidance.
Pharmacokinetics
Peak Effect: PO: 1 to 3 hours after dose
Duration: Half-life 12 hours; supports once-daily dosing
Storage and Handling
Store tablets at controlled room temperature (15 to 30 degrees Celsius). Protect from light. IV solution requires specific storage per manufacturer. Ophthalmic solution is stable at room temperature.
Reconstitution:
Tablets and IV ready-to-use bags require no reconstitution. The IV preparation is supplied as 400 mg in 250 mL NSS, ready to infuse.
TCCC and TECC Role
Moxifloxacin was the TCCC oral wound prophylaxis antibiotic of choice for many years before the cephalosporins (cefadroxil, cephalexin) took primary position. The reasons for the shift include the FDA fluoroquinolone class warnings, concerns about adverse effects with empiric use, and improved evidence supporting cephalosporins for wound prophylaxis. Moxifloxacin remains in TCCC doctrine as an alternative for casualties with penicillin and cephalosporin allergies, and for treatment of established respiratory or intra-abdominal infections in prolonged field care.
Moxifloxacin is the fluoroquinolone that older TCCC providers still associate with wound prophylaxis from the 2004 to 2020 guideline era. The cephalosporin shift was the right call based on evidence and FDA warnings. Moxifloxacin still earns space in deployment medicine kits for respiratory infections, intra-abdominal infections (combined with metronidazole), and as the alternative for true beta-lactam allergic casualties. Watch for tendon symptoms and CNS effects during use.
Using moxifloxacin as first-line wound prophylaxis in casualties with no antibiotic allergies. Current TCCC doctrine specifies cefadroxil or cephalexin for that indication. Reserve moxifloxacin for the appropriate indications (allergy alternative, respiratory, intra-abdominal) rather than as a default wound antibiotic.
This drug profile is provided as educational reference material for trained medical providers. It is not medical advice, not a substitute for formal training, and not a substitute for current published guidelines or medical direction.
Drug administration is governed by your scope of practice, agency standing orders, medical director protocols, and applicable state and federal regulations. Controlled substances are subject to additional handling, accountability, and documentation requirements per DEA and state law. Always verify dosing, indications, contraindications, and route of administration against current published guidelines and your local protocols before administration.
If this content is being viewed during a medical emergency, call 911 immediately and follow the direction of your local emergency dispatch and medical control. Do not use this reference as a substitute for emergency medical services.
Drug information evolves. Last reviewed dates and source citations are provided for each entry. Confirm currency against the cited source before clinical use.
Penn Tactical Solutions publishes this reference for educational purposes. PTS does not provide medical direction and does not assume responsibility for clinical decisions made in the field. Clinical responsibility rests with the administering provider, their medical director, and their agency.
Educational reference for trained medical providers. Not medical advice. Not a substitute for formal training, current published guidelines, or medical direction. Drug administration is governed by your scope of practice, agency standing orders, medical director protocols, and applicable state and federal regulations. Controlled substances require additional storage, accountability, and documentation per DEA and state law.
In a medical emergency, call 911. This reference is not a substitute for emergency medical services.
Verify dosing, indications, and contraindications against current published guidelines and your local protocols before administration. Confirm content currency against the source citation. Penn Tactical Solutions does not provide medical direction. Clinical responsibility rests with the administering provider, their medical director, and their agency.
Moxifloxacin
| IV/IO | Hospital/severe infection: 400 mg IV once daily. Infuse over 60 minutes. (Immediate after infusion) |
| PO | TCCC historical: 400 mg PO once daily. Standard adult dosing: 400 mg PO once daily for 5 to 14 days depending on indication. Community-acquired pneumonia: 5 to 7 days. Complicated skin and soft tissue infection: 7 to 14 days. (1 to 2 hours (high oral bioavailability, approximately 90 percent)) |